Zydus Lifesciences has agreed to pay Astellas Pharma $120 million to settle the U.S. patent litigation with the latter over generic bladder disorder drug Mirabegron | Photo Credit: Reuters Zydus Lifesciences has agreed to pay Astellas Read More
Zydus Lifesciences has agreed to pay Astellas Pharma $120 million to settle the U.S. patent litigation with the latter over generic bladder disorder drug Mirabegron | Photo Credit: Reuters Zydus Lifesciences has agreed to pay Astellas Read More